Lexaria Applauds Eli Lilly's Foundayo(TM) Drug Approval
Rhea-AI Summary
Lexaria (Nasdaq:LEXX) applauded the FDA approval of Eli Lilly's oral GLP-1 drug Foundayo for adult weight control on April 7, 2026. Lexaria highlights expanding oral GLP-1 choices (now three brands) and cites Foundayo's 72-week average weight loss of 27.3 lb (12.4%).
Lexaria notes DehydraTECH has shown side-effect reductions (Study GLP-1-H24-4: 47.9% fewer adverse events vs Rybelsus) and holds 65 issued patents, with additional GLP-1 testing planned in 2026.
Positive
- FDA approval expands oral GLP-1 options to 3 brands
- Foundayo average weight loss: 27.3 lb (12.4%) at 72 weeks
- Study GLP-1-H24-4: 47.9% reduction in adverse events vs Rybelsus
- 65 issued patents covering DehydraTECH globally
- Planned 2026 DehydraTECH testing on additional GLP-1 drugs
Negative
- Foundayo showed higher rates of nausea and GI side effects
- Rybelsus 2025 revenue $3.5B, still under 5% of GLP-1 market
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jan 12 | CEO annual letter | Positive | +3.9% | Annual letter summarizing 2025 R&D, clinical, patent, and financing progress. |
| Dec 30 | Phase 1b data update | Positive | +46.1% | Additional favorable results from Phase 1b GLP-1-H24-4 with safety and tolerability gains. |
| Dec 23 | Phase 1b primary endpoint | Positive | -29.1% | Primary endpoint met with reduced adverse events versus Rybelsus in GLP-1 study. |
| Dec 16 | Registered direct closing | Negative | +0.0% | Closing of $3.5M registered direct equity and warrant financing. |
| Dec 15 | Registered direct offering | Negative | +5.0% | Announcement of $3.5M at-the-market registered direct offering with warrants. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Positive R&D updates have sometimes produced strong gains, but there are multiple instances where favorable clinical news or financings saw flat or negative next-day reactions, indicating inconsistent alignment between news tone and price moves.
Over the last few months, Lexaria highlighted progress in its GLP-1 program and financing activities. On Dec 23, 2025, a Phase 1b study met its primary endpoint with reduced adverse events versus Rybelsus, yet shares fell 29.08%. Additional positive Phase 1b data on Dec 30 coincided with a 46.15% rise. Two registered direct offerings around Dec 15–16 raised roughly $3.5M each, with limited or slightly positive price impact. A CEO annual letter on Jan 12, 2026 outlining R&D and patent gains saw a modest 3.92% gain. Today’s news fits the ongoing GLP-1 and side-effect reduction narrative.
Key Terms
us food and drug administration regulatory
fda regulatory
glucagon-like peptide-1 medical
glp-1 medical
adverse events medical
gastrointestinal medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
The number of oral weight-loss / diabetes drug treatments is expanding, increasing demand for the reduction of side effects
KELOWNA, BC / ACCESS Newswire / April 7, 2026 / Lexaria Bioscience Corp. (Nasdaq:LEXX), (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to recognize that the US Food and Drug Administration ("FDA") has approved Eli Lilly and Company's® Foundayo™ glucagon-like peptide-1 ("GLP-1") agonist (orforglipron) oral tablet for adult use in controlling obesity and weight-related medical conditions.
"This latest approval from the FDA expands choices for Americans searching for the right weight control drug that best suits their needs," said Richard Christopher, CEO of Lexaria Bioscience Corp. "Expanded choices within the historically limited oral weight-loss drug category increases opportunities for Lexaria to partner with the leading companies in the pharmaceutical industry to implement DehydraTECH™ technology to improve patient experiences including through the potential for reduced side effects."
The recent FDA approval of Foundayo™ follows both the December 2025 approval of Wegovy® tablets for weight loss and the September 2019 approval of Rybelsus® tablets for diabetes, bringing the total number of FDA approved GLP-1 oral brand offerings to 3. In 2025, worldwide revenues of the sole oral offering within the GLP-1 category (Rybelsus®) totaled
As Lexaria recently announced, its forward-looking strategic plans for the GLP-1 sector continue to be centered around improving the patient experience while using these drugs for indications including but not limited to diabetes and weight loss, primarily through the reduction of unwanted side effects.
In Eli Lilly's clinical trial, patients taking Foundayo™ (orforglipron) for the full study duration of 72-weeks lost an average of 27.3
According to Eli Lilly, "The most common side effects of Foundayo™ include nausea, constipation, diarrhea, vomiting, indigestion, stomach (abdominal) pain, headache, swollen belly, feeling tired, belching, heartburn, gas, and hair loss. These are not all the possible side effects of Foundayo."
In various studies performed during the past ~2 years, DehydraTECH has already been evaluated orally with semaglutide, liraglutide, and tirzepatide and has successfully reduced side effects with each drug. For example, in Study GLP-1-H24-4, Lexaria reported a
Lexaria has also announced plans to conduct DehyrdaTECH-processed GLP-1 testing in 2026 with additional GLP-1 drugs not previously evaluated, including retatrutide and amycretin, and is considering testing DehydraTECH-processed orforglipron as well. Lexaria believes that reducing adverse events in the GLP-1 drug sector is a significant competitive advantage enjoyed by DehydraTECH technology, which is now backed by 65 issued patents around the world.
About Lexaria Bioscience Corp. & DehydraTECH
DehydraTECH™ is Lexaria's patented drug delivery formulation and processing platform technology which improves the way a wide variety of drugs enter the bloodstream, always through oral delivery. DehydraTECH has repeatedly evidenced the ability to increase bio-absorption, reduce side-effects, and deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 65 patents granted and additional patents pending worldwide. For more information, please visit www.lexariabioscience.com.
CAUTION REGARDING FORWARD-LOOKING STATEMENTS
This press release includes forward-looking statements. Statements as such term is defined under applicable securities laws. These statements may be identified by words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions. Such forward-looking statements in this press release include, but are not limited to, statements by the Company relating to the intended use of proceeds from the offering and relating to the Company's ability to carry out research initiatives, receive regulatory approvals or grants or experience positive effects or results from any research or study. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that the Company will actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements. As such, you should not place undue reliance on these forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, market and other conditions, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process, potential adverse effects arising from the testing or use of products utilizing the DehydraTECH technology, the Company's ability to maintain existing collaborations and realize the benefits thereof, delays or cancellations of planned R&D that could occur related to pandemics or for other reasons, and other factors which may be identified from time to time in the Company's public announcements and periodic filings with the US Securities and Exchange Commission on EDGAR. The Company provides links to third-party websites only as a courtesy to readers and disclaims any responsibility for the thoroughness, accuracy or timeliness of information at third-party websites. There is no assurance that any of Lexaria's postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease. Any forward-looking statements contained in this release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements or links to third-party websites contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.
INVESTOR CONTACT:
George Jurcic - Head of Investor Relations
ir@lexariabioscience.com
Phone: 250-765-6424, ext 202
SOURCE: Lexaria Bioscience Corp.
View the original press release on ACCESS Newswire